Document is current
Any future updates will be listed below
-
Authors
Pang, Kai
Sun, Peilin
Liu, Xinzhi
Yang, Dan
Zhao, Pengfei
Huang, Yongjie
Cao, Shun
Gao, Yang
Chen, Guangyong
Yu, Huajing
Duan, Liping
Yang, Yingchi
Zhang, Zhongtao
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05245474 at ClinicalTrials.govDocuments that mention this clinical trial
Long-course chemoradiation plus concurrent/sequential PD-1 blockade as neoadjuvant treatment for MMR-status-unscreened locally advanced rectal cancer: protocol of a multicentre, phase 2, randomised controlled trial (the POLAR-STAR trial)
https://doi.org/10.1136/bmjopen-2022-069499
Neoadjuvant long-course chemoradiation plus PD1 blockade for locally advanced rectal cancer: Results of a phase 2, open-label, randomized controlled trial.
https://doi.org/10.1200/jco.2024.42.16_suppl.3611
Development of the rationale of a personalized cancer vaccine based on the in situ vaccine effect of radiotherapy: a mechanistic study of the POLARSTAR trial
https://doi.org/10.1007/s00262-025-04229-3
-
Funding
Funding for this research was provided by:
Beijing Postdoctoral Research Foundation (2023-ZZ-038)
Beijing Li Huanying Medical Foundation
- License Information
-
More Information
Article History
Received: 10 July 2025
Accepted: 3 November 2025
First Online: 12 November 2025
Declarations
:
: The authors declare that they have no conflict of interest.
: Consent for publication have been obtained from all individual patients that participated in the POLARSTAR trial.
: The POLARSTAR trial was pre-registered on Clinicaltrials.gov with the identifying number of NCT05245474.
: The randomized POLARSTAR trial was approved and monitored by the ethical committee of Beijing Friendship Hospital, with the identifying serial number of 2022-P2-050-01. All animal experiments were approved by the same committee, with the identifying serial number of 20-2033.
